Document 2796
 DOCN  M94A2796
 TI    The role of hrGM-CSF in neutropenia due to the cytostatic or ganciclovir
       treatment.
 DT    9412
 AU    Szlavik J; Banhegyl D; Miskovits E; Gerlei Z; Saint Laszlo Hospital,
       Department of Immunology, Budapest,; Hungary.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0316). Unique
       Identifier : AIDSLINE ICA10/94369779
 AB    OBJECTIVE: Identification of the role of human recombinant
       granulocyte-monocyte stimulating factor in neutropenia due to cytostatic
       treatment of Kaposi's sarcoma and non-Hodgkin's lymphoma associated with
       AIDS and that of the effectivity of hrGM-CSF in neutropenia due to
       ganciclovir treatment of cytomegalovirus retinitis. METHODS:
       Subcutaneous hrGM-CSF therapy (5 ug/kg/day) was applied for 7-17 days,
       after BACOD therapy in neutropenia of three patients with B-cell
       non-Hodgkin's lymphoma, while cytokine therapy in the same dose was
       applied in neutropenia of two patients with Kaposi's sarcoma due to BVA
       therapy. We tried to treat neutropenia due to inductive application of
       ganciclovir with a dose of 3-5 ug/kg/day of hrGM-CSF in eight patients
       with CMV retinitis. RESULTS: 13 patients (mean age: 32 years) were given
       3-5 ug/kg/day sc. hrGM-CSF for 7-17 days (mean: 9.5). The initial
       neutrophil count 0.3-1.4 x 10(9)/l (mean: 0.7) increased to 1.8-9.3 x
       10(9)/l (mean: 4.2) in the patients with KS and NHL as a result of
       treatment (mean CD4+: 102/mm3). There was a more significant increase in
       the neutrophil count in neutropenia due to ganciclovir treatment
       resulted by seven days treatment from the initial 0.8-2.1 x 10(9)/l
       (mean: 1.1) to 3.6-15.8 x 10(9)/l (mean: 4.2), (mean CD4+: 173/mm3). In
       the investigation period there was no infection observed in association
       with neutropenia, the main adverse effects of hrGM-CSF were fever in 7,
       fatigue and myalgia in 5 and confusion in 1 case. DISCUSSION: Cytokine
       therapy applied in combination is effective in neutropenia due to both
       the cytostatic treatment of tumours and ganciclovir treatment,
       infections associated with neutropenia can be prevented by it, although
       the effect depends on the initial CD4+ lymphocyte count of the patient.
 DE    Adult  Antineoplastic Agents, Combined/*ADVERSE EFFECTS/THERAPEUTIC USE
       Biological Response Modifiers/*THERAPEUTIC USE
       Bleomycins/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Cytomegalovirus Retinitis/DRUG THERAPY  Dexamethasone/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS  Ganciclovir/*ADVERSE EFFECTS  Granulocyte-Macrophage
       Colony-Stimulating Factor/*THERAPEUTIC USE  Human  HIV
       Infections/COMPLICATIONS  Lymphoma, AIDS-Related/DRUG THERAPY
       Neutropenia/CHEMICALLY INDUCED/*THERAPY  Recombinant
       Proteins/THERAPEUTIC USE  Sarcoma, Kaposi's/DRUG THERAPY
       Vincristine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).